PMA device
Abbott Architect Total Psa
Abbott Laboratories · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF, Class III) · First FDA decision Feb 2, 2004, newest Mar 22, 2011Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
3
Naming "Abbott Architect"
MAUDE reports
2
Brand "Abbott Architect", since 2015
PubMed studies
737
Mentioning "Abbott Architect"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Abbott Architect Total Psa
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- ABBOTT ARCHITECT TOTAL PSAPMA supplement
P910007-S019 · Decided Mar 22, 2011 · 239 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
- ABBOTT ARCHITECT TOTAL PSAPMA supplement
P910007-S007 · Decided Feb 2, 2004 · 789 days after receipt · Normal 180 Day Track
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Abbott Architect", any status and sponsor, newest update first.
- Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site SettingsPivotal-lookingCompleted
bioLytical LaboratoriesNot on our public-company list
NCT06368479 · 1,400 participants · Start Mar 19, 2024 · Primary completion Jul 19, 2024
Device: iStatis HBsAg Test · For: Hepatitis B; Hepatitis B Infection
Sites: Hillcrest, South Africa
bioLytical LaboratoriesNot on our public-company list
NCT06367621 · 1,500 participants · Start Nov 15, 2023 · Primary completion Apr 15, 2024
Device: iStatis Syphilis Antibody Test · For: Syphilis; Syphilis Infection
Sites: Hillcrest, South Africa
bioLytical LaboratoriesNot on our public-company list
NCT06365606 · 1,500 participants · Start Mar 14, 2024 · Primary completion May 13, 2024
Device: iStatis Syphilis Ab Test · For: Syphilis Infection; Syphilis
Sites: Hillcrest, South Africa
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Abbott Architect", and for the whole product code for context.
This brand
2 reports: 2 malfunction, 0 injury, 0 death
Whole product code MTF
390 reports: 373 malfunction, 17 injury, 0 death
Newest reports for this brand
3016438761-2026-00399 · Received Jul 22, 2026 · Event dated Jul 13, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: Thermal Decomposition of Device
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
MW5099878 · Received Mar 9, 2021 · Event dated Feb 22, 2021 · 1 other device named on this report
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: False Positive Result
Patient problem as coded: Insufficient Information
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Abbott Architect"[tiab]. The summary above synthesizes these.
- Total hCG tests.
Cole LA, DuToit S, Higgins TN · Clin Chim Acta · 2011
- Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer.
Stricker R, Eberhart R, Chevailler MC, et al. · Clin Chem Lab Med · 2006
- Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin.
Ylli D, Soldin SJ, Stolze B, et al. · Thyroid · 2021Research Support, Non-U.S. Gov't
- Performance of the Abbott Architect Immuno-Chemiluminometric NT-proBNP Assay.
Lau CS, Liang YL, Phua SK, et al. · Diagnostics (Basel) · 2022
- Laboratory assessment of vitamin K status.
Card DJ, Gorska R, Harrington DJ · J Clin Pathol · 2020Review
- Longitudinal evaluation of the Abbott ARCHITECT SARS-CoV-2 IgM and IgG assays in a pediatric population.
Interiano C, Muze S, Turner B, et al. · Pract Lab Med · 2021
- Assessment of Abbott Architect 25-OH vitamin D assay in different levels of vitamin D.
Avci E, Demir S, Aslan D, et al. · J Med Biochem · 2020
- Evaluation of High-Throughput Serological Tests for SARS-CoV-2.
Loeffelholz MJ · J Clin Microbiol · 2020Comment
- Thyroid Hormone Reference Intervals among Healthy Individuals In Lanzhou, China.
Lu Y, Zhang WX, Li DH, et al. · Endocrinol Metab (Seoul) · 2023Research Support, Non-U.S. Gov't
- Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Lim YJ, Ward V, Brown A, et al. · Br J Haematol · 2024Clinical Trial, Phase III, Multicenter Study
- kEDTA Sample Contamination: A Reappraisal.
Chadwick K, Whitehead SJ, Ford C, et al. · J Appl Lab Med · 2019Research Support, Non-U.S. Gov't
- Abbott ARCHITECT Syphilis TP Chemiluminescent Immunoassay Accurately Diagnoses Past or Current Syphilis in Pregnancy.
Adhikari EH, Frame IJ, Hill E, et al. · Am J Perinatol · 2020Evaluation Study
Other devices of this type
Also filed under product code MTF.
- Elecsys total PSA, total PSA CalSet IIRoche Diagnostics Corp. · PMA 2023
- ARCHITECT Total PSA, Alinity i Total PSAAbbott Laboratories · PMA 2023
- Access Hybritech PSABeckman Coulter, Inc. · PMA 2024
- Dimension Vista Tpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Atellica IM Total PSA II (tPSAII)Siemens Healthcare Diagnostics, Inc. · PMA 2026
- Advia Centaur Psa AssaySiemens Healthcare Diagnostics · PMA 2017
- Axsym Total PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 Psa & 3RD Generation PsaSiemens Healthcare Diagnostics, Inc. · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.